European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS

Children’s Liver Tumour European Research Network

Objectif

Liver cancer in the paediatric population is rare with an incidence approximately 1-1.5 per million population. The commonest tumour seen in the childhood population is hepatoblastoma (HB), usually seen in young children and infants. Much rarer (about 10% of paediatric liver cancers) is hepatocellular carcinoma (HCC), usually seen in the teenage population and sometimes associated with underlying cirrhotic liver diseases. The ChiLTERN project relates to topic PHC 18 ‘establishing effectiveness of health care interventions in the paediatric population’. The ChiLTERN project builds on a unique opportunity to undertake a comprehensive research programme linked to an ambitious global partnership which will see the single largest clinical trial (the Paediatric Hepatic International Tumour Trial - PHITT) ever undertaken in this population of patients, with several randomised questions in six subgroups of patients. ChiLTERN will allow us to move towards an era of personalised therapy in which each patient will receive the correct amount of chemotherapy and will undergo has the best surgical operation (surgical resection or liver transplant). By using both clinical and biological information, we can assign patients more accurately to risk groups based on their survival. Using genetic tests and biomarkers, we will determine those children who may be at risk of developing long term side effects (deafness, heart failure, kidney damage). In addition, biomarkers will allow us to monitor during therapy and detect toxicities early before serious damage is done so that we can adapt treatment and prevent these problems. Finally, we will be using imaging technology tools which will help our surgeons plan liver operations more safely and effectively. Ultimately ChiLTERN will allow us to cure more children with liver cancer, expose fewer children to toxic chemotherapy and ensure their surgery is both effective and safe.

Champ scientifique

Programme(s)

Thème(s)

Appel à propositions

H2020-PHC-2014-2015

Voir d’autres projets de cet appel

Sous appel

H2020-PHC-2015-two-stage

Régime de financement

RIA - Research and Innovation action

Coordinateur

THE UNIVERSITY OF BIRMINGHAM
Contribution nette de l'UE
€ 2 676 440,35
Adresse
Edgbaston
B15 2TT Birmingham
Royaume-Uni

Voir sur la carte
Région
West Midlands (England) West Midlands Birmingham
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
€ 2 676 440,35

Participants (29)

Partager cette page

Télécharger

Dernière mise à jour: 17 Janvier 2023

Mon livret

Permalink: https://cordis.europa.eu/project/id/668596/fr

European Union, 2024